Advanced Life Sciences Expands Collaboration with U.S. Government to Study Restanza(TM) as Treatment for Sexually Transmitted Infections
CHICAGO, May 28 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the expansion of its collaboration with the U.S. Government to include the evaluation of Restanza's activity against sexually transmitted infections (STI's), such as gonorrhea. Under the expanded agreement, Restanza's in vitro activity against Neisseria gonorrhoeae and other key STI's will be assessed, with the potential to advance Restanza into clinical development in government-sponsored clinical trials.
The activity of Restanza has been evaluated against 148 N. gonorrhoeae isolates and demonstrated significant in vitro activity as measured by minimal inhibitory concentration (MIC), the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism. Restanza was comparable in activity to azithromycin and ciprofloxacin and superior to erythromycin and clarithromycin, the antibiotics commonly used to treat gonorrhea infections.
"We believe that Restanza has demonstrated significant promise
as a potent treatment for gonorrhea and other sexually transmitted
infections and we are excited to expand our partnership with the
U.S. Government beyond biodefense to further explore its
therapeutic activity," said Dr. '/>"/>